4 completed, 4 recruiting, 4 unknown, 2 active not recruiting. 6 Phase 2, 3 Not applicable, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 3, Active not recruiting 1, Completed 1, Recruiting 1 |
| Not applicable | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 3 | Completed 1, Suspended 1, Unknown 1 |
Follow Pathological Complete Response: new trials by email Literature Review of Pathological Complete Response trials Research Report on Pathological Complete Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer Breast Cancer, Axillary Lymph Node Metastasis | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 150 | 2026-05-20 | 2026-05-19 | |
| Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer Breast Cancer, Invasive Breast Carcinoma | Not yet recruiting | Atlas University | 60 | 2026-04-12 | 2026-03-30 | |
| Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning No interventions - Rectal Cancers, Pathological Complete Response | Active not recruiting | Peking University People's Hospital | 320 | 2026-02-04 | 2026-04-03 | |
| Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - ESCC, Total Neoadjuvant Treatment | Phase 2 | Recruiting | National Taiwan University Hospital | 50 | 2025-07-23 | 2026-01-27 |
| Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy The high-throughput extraction of large amounts of quantitative image features from medical images - Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy | Recruiting | Tongji Hospital | 300 | 2025-03-01 | 2025-07-28 | |
| Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy No interventions - Deep Learning Model, Pathological Complete Response | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1000 | 2024-03-01 | 2024-03-13 | |
| Omission of ALND in Breast Cancer Patients With Axillary pCR Stained region Lymph Node Biopsy (SrLNB), Regional lymph node radiotherapy (RNI) including the axilla - Axillary Lymph Node Dissection, Pathological Complete Response | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 92 | 2023-09-11 | 2024-12-30 |
| Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Fasting Mimicking diet program - Fasting Mimicking Diet, HER2-negative Breast Cancer | Phase 3 | Suspended | Leiden University Medical Center | 10 | 2023-03-17 | 2023-11-22 |
| Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma Sintilimab combined with XELOX - Pathological Complete Response, Rectal Cancer | Phase 2 | Active not recruiting | The First Affiliated Hospital of Anhui Medical University | 50 | 2022-06-01 | 2025-11-21 |
| Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Camrelizumab with vinorelbine and cisplatin - HER2-negative Breast Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Peking University First Hospital | 30 | 2021-11-20 | 2022-10-18 |
| THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT - Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer | Not applicable | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 179 | 2021-03-17 | 2026-07-10 |
| Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT) - Esophageal Squamous Cell Carcinoma, Pathological Complete Response | Completed | Nanjing Medical University | 363 | 2019-01-01 | 2025-09-18 | |
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX - Rectal Cancer, Pathological Complete Response | Phase 2 | Unknown | Peking University People's Hospital | 244 | 2018-01-31 | 2023-03-22 |
| Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Epirubicin, Fluorouracil, Docetaxel - Breast Cancer, Pathological Complete Response | Phase 2 / Phase 3 | Unknown | Zhiyong Yu | 200 | 2017-11-27 | 2017-11-21 |
| RISAS Procedure in Node Positive Breast Cancer Following NAC RISAS - Breast Neoplasm, Neoadjuvant Therapy | Not applicable | Completed | Erasmus Medical Center | 248 | 2017-03-30 | 2022-02-10 |
| DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer Fasting mimicking diet - Fasting Mimicking Diet, Breast Cancer | Phase 2 / Phase 3 | Completed | Leiden University Medical Center | 131 | 2014-02-01 | 2019-10-24 |
| Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade neoadjuvant therapy - Pancreatic Cancer, Neoadjuvant Therapy | Completed | Seoul National University Hospital | 462 | 2009-01-01 | 2024-10-08 |
Breast Neoplasms (6) · Rectal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Pancreatic Neoplasms (1)
Neoplasms (13) · Neoplasms by Site (13) · Breast Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Colorectal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Rectal Diseases (3) · Carcinoma (2) · Carcinoma, Squamous Cell (2)
Cisplatin (2) · Chemoradiotherapy (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Epirubicin (1) · Fluorouracil (1) · Neoadjuvant Therapy (1) · Paclitaxel (1) · Vinorelbine (1) · XELOX (1) · camrelizumab (1) · tislelizumab (1)
Leiden University Medical Center (2) · Peking University People's Hospital (2) · Atlas University (1) · Erasmus Medical Center (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Nanjing Medical University (1) · National Taiwan University Hospital (1) · Peking University First Hospital (1) · Seoul National University Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The First Affiliated Hospital of Anhui Medical University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Tongji Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Zhiyong Yu (1)
China (8) · Netherlands (3) · Italy (1) · Taiwan (1)
Ernest JT Luiten, MD, PhD (1) · Giuditta Chiloiro, MD PhD (1) · Hanno Pijl, MD PhD (1) · Hong-Peng Jiang, docter (1) · Judith R Kroep, MD, PhD (1) · Judith R Kroep, PhD (1) · Linetta B Koppert, MD, PhD (1) · Marjolein L Smidt, MD, PhD (1) · Xiaoshan Cao, MD (1) · Yangkai Li, MD, PhD (1) · Zhiyong Yu, PhD (1)
PMID 20106720, PMID 21066983, PMID 21596621, PMID 21747092, PMID 22367706, PMID 22529255, PMID 26187751, PMID 26189067, PMID 27254838, PMID 27480145, PMID 32576828, PMID 33179154, PMID 35033008, PMID 38263134, PMID 38890720, PMID 39221992, PMID 39302345, PMID 40105813, PMID 40164484, PMID 41127561, PMID 42551632